Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Transl Stroke Res. 2014 Apr 12;5(3):316–329. doi: 10.1007/s12975-014-0343-0

Fig. 1. Novel theories of AVM initiation and progression, and new therapeutic targets.

Fig. 1

EC: endothelial cell; BMDC: bone marrow-derived cells; sFLT: soluble FMS-related tyrosine kinase 1 (sFLT1), also called VEGF receptor-1